Therapeutics Company Announces Major Clinical Collaboration With Merck
Prelude Therapeutics and Merck Announce Clinical Collaboration to Evaluate PRT3789 with KEYTRUDA® in SMARCA4-Mutated Cancers.
On July 10, 2024, Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, announced a clinical collaboration with Merck. This collaboration aims to evaluate the efficacy of Prelude's investigational drug, PRT3789, in combination with Merck's established anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). The combined treatment will target patients with SMARCA4-mutated cancers, a mutation known to present limited treatment options. $Prelude Therapeutics (PRLD.US)$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
